Clinical Trial Update: Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major Depression [Phase 3]

View source ↗

Summary

Open-label Phase 3 trial evaluating once-daily duloxetine for stabilization dosing in adults with major depressive disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• Cymbalta (duloxetine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Major Depressive Disorder | Phase 3 | Status: COMPLETED